Eagle Asset Management Inc Ultragenyx Pharmaceutical Inc. Transaction History

Eagle Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$92.19 - $115.71 $32.5 Million - $40.8 Million	-352,860 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$106.9 - $167.73 $2.71 Million - $4.24 Million	25,307 Added 7.73%	352,860 $39.9 Million
Q4 2020 Feb 12, 2021	SELL	$84.4 - $177.39 $1.96 Million - $4.13 Million	-23,268 Reduced 6.63%	327,553 $45.3 Million
Q3 2020 Nov 12, 2020	BUY	$72.98 - $90.0 $5.52 Million - $6.8 Million	75,574 Added 27.46%	350,821 $29.9 Million
Q2 2020 Aug 12, 2020	BUY	$46.91 - $78.22 $12.9 Million - $21.5 Million	275,247 New	275,247 $20.3 Million
Q4 2017 Feb 09, 2018	SELL	$43.54 - $57.32 $20.7 Million - $27.3 Million	-475,875 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$49.79 - $66.32 $23.7 Million - $31.6 Million	475,875	475,875 $27.3 Million

329

85.9M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.18B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.